Tumor Localization by Immunoscintigraphy: Potential and Limitations

  • S. Matzku
  • H. Bihl
Conference paper

Abstract

It is worth remembering that positive tumor localization with labeled antibodies was one of the founder technologies of nuclear medicine (for review see [1]). However, the enthusiastic approaches in the 1950s were abandoned when it became clear that the target structures detected by the then available polyclonal antitumor antisera were not actually tumor-specific at all, but, for example, directed against ectopic normal components such as peritumoral fibrin [2–4]

Keywords

Toxicity Lymphoma Leukemia Iodine Oncol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pressman D (1980) The development and use of radiolabeled antitumor antibodies. Cancer Res 40:2960–2964PubMedGoogle Scholar
  2. 2.
    Dewey WC, Bale WF, Rose RG, Marrack D (1963) Localization of antifibrin antibodies in human tumors. Acta Un Int Cancer 19:187–196Google Scholar
  3. 3.
    Spar IL, Bale WF, Marrack D, Dewey WC, McCardle RJ, Harper PV (1967) 1311-labeled antibodies to human fibrin. Cancer 20:865–870Google Scholar
  4. 4.
    Bale WF, Contreras MA, Grady ED (1980) Factors influencing localization of labeled antibodies to tumors. Cancer Res 40:2965–2972PubMedGoogle Scholar
  5. 5.
    Gold P, Freedman SO (1965) Specific carcinoembryonic antigens of the human digestive system. J Exp Med 122:467–481PubMedCrossRefGoogle Scholar
  6. 6.
    Gold P, Shuster J (1980) Historical development and potential uses of tumor antigens as markers of human cancer growth. Cancer Res 40:2973–2976PubMedGoogle Scholar
  7. 7.
    Ruoslahti E, Seppala M (1971) Studies of carcinofetal protein: III. Demonstration of alpha-fetoprotein in serum of healthy adults. Int J Cancer 8:374–379PubMedCrossRefGoogle Scholar
  8. 8.
    Kim EE, Deland FH, Nelson MO, Bennett S, Simmons G, Alpert E, Goldenberg DM (1980) Radioimmunodetection of cancer with radiolabeled antibodies to alpha-fetoprotein. Cancer Res 40:3008–3012PubMedGoogle Scholar
  9. 9.
    Mach J-P, Carrel S, Merenda C (1974) In vivo localization of radiolabeled antibodies to carcinoembryonic antigen in human colon carcinoma grafted into nude mice. Nature 248:704–706PubMedCrossRefGoogle Scholar
  10. 10.
    Goldenberg DM, DeLand F, Kim E, Bennett S, Primus FJ, van Nagell JR, Estes N, DeSimone P, Rayburn P (1978) Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 298:1384–1388PubMedCrossRefGoogle Scholar
  11. 11.
    Mach J-P, Buchegger F, Forni M, Ritschard J, Berche C, Lumbroso J-D, Schreyer M, Girardet C, Accolla RS, Carrel S (1981) Use of radiolabeled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy. Immunol Today 2:239–249CrossRefGoogle Scholar
  12. 12.
    Hnatowich DJ, Childs RL, Lanteigne D, Najafi A (1983) The preparation of DTPA-coupled antibodies radiolabeled with metallic radionuclides: an improved method. J Immunol Methods 65:147–157PubMedCrossRefGoogle Scholar
  13. 13.
    Meares CF, McCall MJ, Reardan DT, Goodwin DA, Diamanti CI, McTigue M (1984) Conjugation of antibodies with Afunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem 142:68–78PubMedCrossRefGoogle Scholar
  14. 14.
    Mather SJ, Ellison D (1990) Reduction-mediated technetium-99m labeling of monoclonal antibodies. J Nucl Med 31:692–697PubMedGoogle Scholar
  15. 15.
    Fritzberg AR (1987) Advances in the 99mTc-labeling of antibodies. Nucl Med 26:7–12Google Scholar
  16. 16.
    Wilson CB, Snook DE, Dhokia B, Taylor CVJ, Watson IA, Lammertsma AA, Lambrecht R, Waxman J, Jones T, Epenetos AA (1991) Quantitative measurement of monoclonal antibody distribution and blood flow using positron emission tomography and 124iodine in patients with breast cancer. Int J Cancer 47:344–347PubMedCrossRefGoogle Scholar
  17. 17.
    Crowther ME, Britton KE, Granowska M, Shepherd JH (1989) Monoclonal antibodies and their usefulness in epithelial ovarian cancer. Br J Obstet Gynaecol 96:516–521PubMedCrossRefGoogle Scholar
  18. 18.
    Baum RP, Lorenz M, Senekowitsch R, Chatal JF, Saccavini JC, Hottenrott C, et al. (1988) Clinical experience in cancer diagnosis with radiolabeled monoclonal antibodies in 200 patients and initial attempts at radioimmunotherapy. In: Srivastava SC (ed) Radiolabeled monoclonal antibodies for imaging and therapy. Plenum, New York, pp 613–651Google Scholar
  19. 19.
    Wagner HN Jr (1991) Molecular medicine: from science to service. J Nucl Med 32:11N-23NPubMedGoogle Scholar
  20. 20.
    Sun LK, Curtis P, Rakowicz-Szulczynska E, Ghrayeb J, Chang N, Morrison SL, Koprowski H (1987) Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17–1 A. Proc Natl Acad Sci USA 84:214–218PubMedCrossRefGoogle Scholar
  21. 21.
    Riechmann L, Clark M, Waldmann H, Winter G (1988) Reshaping human antibodies for therapy. Nature 332:323–327PubMedCrossRefGoogle Scholar
  22. 22.
    Hale G, Dyer MJ, Clark MR, Phillips JM, Marcus R, Riechmann L, Winter G, Waldmann H (1988) Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 2:1394–1399PubMedCrossRefGoogle Scholar
  23. 23.
    Meredith RF, LoBuglio AF, Plott WE, Orr RA, Brezovich IA, Russell CD, Harvey EB, Yester MV, Wagner AJ, Spencer SA, Wheeler RH, Saleh MN, Rogers KJ, Polansky A, Salter MM, Khazaeli MB (1991) Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/ human IgGl,k 17–1A monoclonal antibody. J Nucl Med 32:1162–1168PubMedGoogle Scholar
  24. 24.
    LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB (1989) Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response. Proc Natl Acad Sci USA 86:4220–4224PubMedCrossRefGoogle Scholar
  25. 25.
    Saga T, Endo K, Akiyama T, Sakahara H, Koizumi M, Watanabe Y, Nakai T, Hosono M, Yamamoto T, Toyoshima K, Konishi J (1991) Scintigraphic detection of overexpressed c-erbB-2 protooncogene products by a class-switched murine anti-c-erbB-2 protein monoclonal antibody. Cancer Res 51:990–994PubMedGoogle Scholar
  26. 26.
    Divgi CR, Welt S, Kris M, Real FX, Yeh SDJ, Gralla R, Merchant B, Schweighart S, Unger M, Larson SM, Mendelsohn J (1991) Phase I and imaging trial of indium Ill-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 83:97–104PubMedCrossRefGoogle Scholar
  27. 27.
    Kalofonos HP, Pawlikowska TR, Hemingway A, Courtenay-Luck N, Dhokia B, Snook D, Sivolapenko GB, Hooker GR, McKenzie CG, Lavender PJ, Thomas DGT, Epenetos AA (1989) Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J Nucl Med 30:1636–1645PubMedGoogle Scholar
  28. 28.
    Bale WF, Spar IL, Goodland RL (1960) Experimental radiation therapy of tumors with 131I carrying antibodies to fibrin. Cancer Res 20:1488–1494PubMedGoogle Scholar
  29. 29.
    Pezzutto A, Dorken B, Rabinovitch PS, Ledbetter JA, Moldenhauer G, Clark EA (1987) CD 19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J Immunol 138:2793–2799PubMedGoogle Scholar
  30. 30.
    Badger CC, Bernstein ID (1986) Prospects for monoclonal antibody therapy of leukemia and lymphoma. Cancer 58:584–589PubMedCrossRefGoogle Scholar
  31. 31.
    DeNardo GL, DeNardo SJ, O’Grady LF, Levy NB, Adams GP, Mills SL (1990) Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-l. Cancer Res 50 [Suppl]: 1014s-1016sGoogle Scholar
  32. 32.
    Parker BA, Vassos AB, Halpern SE, Miller RA, Hupf H, Amox DG, Simoni JL, Starr RJ, Green MR, Royston I (1990) Radioimmunotherapy of human B-cell lymphoma with 90Y-conjugated antiidiotype monoclonal antibody. Cancer Res 50 [Suppl]:1022s-1028sPubMedGoogle Scholar
  33. 33.
    Goldenberg DM, Horowitz JA, Sharkey RM, Hall TC, Murthy S, Goldenberg H, Lee RE, Stein R, Siegel JA, Izon DO, Burger K, Swayne LC, Belisle E, Hansen HJ, Pinsky CM (1991) Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 9:548–564PubMedGoogle Scholar
  34. 34.
    Eary JF, Press OW, Badger CC, Durack LD, Richter KY, Addison SJ, Krohn KA, Fisher DR, Porter BA, Williams DL, Martin PJ, Appelbaum FR, Levy R, Brown SL, Miller RA, Nelp WB, Bernstein ID (1990) Imaging and treatment of B-cell lymphoma. J Nucl Med 31:1257–1268PubMedGoogle Scholar
  35. 35.
    Morton BA, Beatty BG, Mison AP, Wanek PM, Beatty JD (1990) Role of bone marrow transplantation in 90Y antibody therapy of colon cancer xenografts in nude mice. Cancer Res 50 [Suppl]:1008s-1010sPubMedGoogle Scholar
  36. 36.
    Goodwin DA (1988) Pharmacokinetics and antibodies. J Nucl Med 28: 1358–1362Google Scholar
  37. 37.
    Wilbur DS, Hadley SW, Hylarides MD, Abrams PG, Beaumier PA, Morgan AC, Reno JM, Fritzberg AR (1989) Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer. J Nucl Med 30:216–226PubMedGoogle Scholar
  38. 38.
    Badger CC, Wilbur DS, Hadley SW, Fritzberg AR, Bernstein ID (1990) Biodistribution of p-iodobenzoyl (PIP) labeled antibodies in a murine lymphoma model. Nucl Med Biol 17:381–387Google Scholar
  39. 39.
    Zalutsky MR, Narula AS (1988) Radiohalogenation of a monoclonal antibody using an N-succinimidyl 3-(tri-n-butylstannyl) benzoate intermediate. Cancer Res 48:1446–1450PubMedGoogle Scholar
  40. 40.
    Brady LW, Markoe AM, Woo DV, Amendola BE, Karlsson UL, Rackover M, Koprowski H, Steplewski Z, Peyster RG (1990) Iodine-125-labeled anti-epidermal growth factor receptor-425 in the treatment of glioblastoma multiforme. Ant Immun Radiopharm 24:151–160Google Scholar
  41. 41.
    Sharkey RM, Kaltovich FA, Shih LB, Fand I, Govelitz G, Goldenberg DM (1988) Radioimmunotherapy of human colonic cancer xenografts with 90 Y-labeled monoclonal antibodies to Carcinoembryonic antigen. Cancer Res 48:3270–3275PubMedGoogle Scholar
  42. 42.
    Esteban JM, Hyams DM, Beatty BG, Wanek P, Beatty JD (1989) Effect of yttrium-90-labeled anti-carcinoembryonic antigen monoclonal antibody on the morphology and phenotype of human tumors grown as peritoneal carcinomatosis in athymic mice. Cancer 63:1343–1352PubMedCrossRefGoogle Scholar
  43. 43.
    Deshpande SV, DeNardo SJ, Kukis DL, Moi MK, McCall MJ, DeNardo GL, Meares CF (1990) Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med 31:473–479Google Scholar
  44. 44.
    Vanderheyden J-L, Su F-M, Venkatesan P, Beaumier P, Bugaj J, Fritzberg AR (1990) The chemistry of rhenium-186 labeled antibodies and F(ab’)2 fragments for RIT in animals and man. J Nucl Med 31:823Google Scholar
  45. 45.
    Cobb LM (1989) Intratumour factors influencing the access of antibody to tumour cells. Cancer Immunol Immunother 28:235–240PubMedCrossRefGoogle Scholar
  46. 46.
    Jain RK (1990) Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 50 [Suppl]:814s-819sPubMedGoogle Scholar
  47. 47.
    Fujimori K, Covell DG, Fletcher JE, Weinstein JN (1989) Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab’)2, and Fab in tumors. Cancer Res 49:5656–5663PubMedGoogle Scholar
  48. 48.
    Skerra A, Pfitzinger I, Pliickthun A (1991) The functional expression of antibody Fv fragments in Escherichia coli: improved vectors and a generally applicable purification technique. Biotechnology 9:273–278PubMedCrossRefGoogle Scholar
  49. 49.
    Ward ES, Giissow D, Griffiths AD, Jones PT, Winter G (1989) Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341:544–546PubMedCrossRefGoogle Scholar
  50. 50.
    Larson SM (1990) Improved tumor targeting with radiolabeled, recombinant, single-chain, antigenbinding protein. J Natl Cancer Inst 82:1173–1175PubMedCrossRefGoogle Scholar
  51. 51.
    Reardan DT, Meares CF, Goodwin DA (1985) Antibody against metal chelates. Nature 316:265–268PubMedCrossRefGoogle Scholar
  52. 52.
    Goodwin DA, Meares CF, McCall MJ, McTigue M, Chaovapong W (1988) Pre-targeted immunoscintigraphy of murine tumors with indium-lll-labeled bifunctional haptens. J Nucl Med 29:226–234PubMedGoogle Scholar
  53. 53.
    Le Doussal J-M, Martin M, Gautherot E, Delaage M, Barbet J (1989) In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 30:1358–1366PubMedGoogle Scholar
  54. 54.
    Le Doussal J-M, Gautherot E, Martin M, Barbet J, Delaage M (1991) Enhanced in vivo targeting of an asymmetric bivalent hapten to double-antigen-positive mouse B cells with monoclonal antibody conjugate cocktails. J Immunol 146:169–175PubMedGoogle Scholar
  55. 55.
    Gridley DS, Ewart KL, Cao JD, Stickney DR (1991) Hyperthermia enhances localization of nlIn-labeled hapten to bifunctional antibody in human colon tumor xenografts. Cancer Res 51:1515–1520PubMedGoogle Scholar
  56. 56.
    Schuhmacher J, Matys R, Hauser H, Maier-Borst W, Matzku S (1986) Labeling of monoclonal antibodies with a 67Ga-phenolic aminocarboxylic acid chelate: I. Chemistry and labeling technique. Eur J Nucl Med 12:197–404CrossRefGoogle Scholar
  57. 57.
    Matzku S, Moldenhauer G, Kalthoff H, Canevari S, Colnaghi MI, Schuhmacher J, Bihl H (1990) Antibody transport and internalization into tumors. Br J Cancer 62 (S.X):1–5Google Scholar
  58. 57a.
    Schuhmacher J, Klivenyi G, Hull WE, Matys R, Hauser H, Kalthoff H, Schmiegel W, Maier-Borst W, Matzku S (1992) A bifunctional HBED-derivative for labeling of antibodies with Ga, In and Fe. Comparative biodistribution in mice bearing antibody internalizing and non-internalizing tumors. Nucl Med Biol (in press)Google Scholar
  59. 58.
    Hnatowich DJ, Virzi F, Ruschkowski M (1987) Investigations of avidin and biotin for imaging applications. J Nucl Med 28:1294–1302PubMedGoogle Scholar
  60. 59.
    Paganelli G, Pervez S, Siccardi AG, Rowlinson G, Deleide G, Chiolerio F, Malcovati M, Scassellati GA, Epenetos A A (1990) Intraperitoneal radio-localization of tumors pre-targeted by biotinylated monoclonal antibodies, Int J Cancer 45:1184–1189PubMedCrossRefGoogle Scholar
  61. 60.
    Paganelli G, Magnani P, Rossetti C, Zito F, Belloni C, Pasini A, Sassi I, Sanvito F, Siccardi AG, Fazio F (1990) Antibody guided tumor detection in CEA positive patients using the avidin-biotin system. J Nucl Med 31:735 (abstr)Google Scholar
  62. 61.
    Schatten C, Pateisky N, Vavra N, Ehrenbock P, Angelberger P, Sivolapenko G, Epenetos A (1991) Lymphoscintigraphy with 123I-labelled epidermal growth factor. Lancet 337:395–396PubMedCrossRefGoogle Scholar
  63. 62.
    Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP (1990) Somatostatin receptor imaging in the localization of endocrine tumors. N Engl J Med 323:1246–1249PubMedCrossRefGoogle Scholar
  64. 63.
    Bakker WH, Krenning EP, Breeman WA, Kooij PP, Reubi JC, Koper JW, deJong M, Lameris JS, Vieers TJ, Lamberts SW (1991) The in vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism, and binding to somatostatin receptor-positive tumors in man. J Nucl Med 32:1184–1188PubMedGoogle Scholar
  65. 64.
    Larson SM (1991) Receptors on tumors studies with radionuclide scintigraphy. J Nucl Med 32:1189–1191PubMedGoogle Scholar
  66. 65.
    Order SE, Stillwagon GB, Klein JL, Leichner PK, Siegelman SS, Fishman EK, Ettinger DS, Haulk T, Kopher K, Finney K, Surdyke M, Self S, Leibel S (1985) Iodine 131 antiferritin, a new treatment modality in hepatoma: a Ratiation Therapy Oncology Group Study J Clin Oncol 3:1573–1582PubMedGoogle Scholar
  67. 66.
    Rosen ST, Zimmer AM, Goldman-Leikin R, et al. (1987) Radio-immunodetection and radioimmunotheraphy of cutaneous T-cell lymphomas using an I-131-labeled monoclonal antibody: an Illinois Cancer Council study. J Clin Oncol 5:562–573PubMedGoogle Scholar
  68. 67.
    Press OW, Eary JF et al. (1989) Treatment of refractory NHLs with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 7:1027–1038PubMedGoogle Scholar
  69. 68.
    Bergh J, Nilsson S, Liljedahl C, Sivolapenko G, Maripuu E, Stavrou D, Epenetos A (1990) In vivo imaging and treatment of human brain tumours utilizing the radiolabeled monoclonal antibody MUC 2–63 Anticancer Res 10:655–660PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • S. Matzku
    • 1
  • H. Bihl
    • 2
  1. 1.Abteilung ImmunchemiePharmaforschung E. MerckDarmstadtGermany
  2. 2.Klinik für NuklearmedizinKatharinenhospitalStuttgartGermany

Personalised recommendations